{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T20:30:58Z","timestamp":1770150658593,"version":"3.49.0"},"reference-count":22,"publisher":"BMJ","issue":"8","funder":[{"name":"Honeylab NZ"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,6,22]]},"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Worldwide, about 90% of people are infected with the herpes simplex virus, 30% of whom will experience recurrent herpes simplex labialis, commonly referred to as \u2018cold sores\u2019, which can last up to 10 days. The most common treatment is aciclovir cream which reduces healing time by just half a day compared with no specific treatment. This is a protocol for a randomised controlled trial (RCT) to determine the efficacy of medical grade kanuka honey-based topical treatment (Honevo) in reducing the healing time and pain of cold sores, compared with topical aciclovir treatment (Viraban).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This open-label, parallel-group, active comparator superiority RCT will compare the efficacy of medical grade kanuka honey with 5% aciclovir cream in the treatment of cold sores in the setting of a pharmacy research network of 60 sites throughout New Zealand. Adults presenting with a cold sore (N=950) will be randomised by pharmacy-based investigators. The pharmacy-based investigators will dispense the investigational product to randomised participants and both study groups apply the treatment five times daily until their skin returns to normal or for 14 days, whichever occurs first. In response to a daily SMS message, participants complete an assessment of their cold sore healing, with reference to a visual guide, and transmit it to the investigators by a smartphone eDiary in real time. The primary outcome variable is time (in days) from randomisation to return to normal skin. Secondary endpoints include total healing time stratified by stage of the lesion at onset of treatment, highest pain severity and time to pain resolution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>New Zealand Ethics Registration 15\/NTB\/93. Results will be published in a peer-reviewed medical journal, presented at academic meetings and reported to participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>Australia New Zealand Clinical Trials Registry: ACTRN12615000648527, pre-results.<\/jats:p>\n                    <jats:p>SCOTT Registration: 15\/SCOTT\/14<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Protocol version<\/jats:title>\n                    <jats:p>4.0 (12 June 2017)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-017766","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T20:10:21Z","timestamp":1501791021000},"page":"e017766","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Protocol for a randomised controlled trial of 90% kanuka honey versus 5% aciclovir for the treatment of herpes simplex labialis in the community setting"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0949-0555","authenticated-orcid":false,"given":"Alex","family":"Semprini","sequence":"first","affiliation":[{"name":"Medical Research Institute of New Zealand, Wellington, New Zealand"},{"name":"Victoria University Wellington, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Singer","sequence":"additional","affiliation":[{"name":"Medical Research Institute of New Zealand, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Shortt","sequence":"additional","affiliation":[{"name":"Medical Research Institute of New Zealand, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5327-3027","authenticated-orcid":false,"given":"Irene","family":"Braithwaite","sequence":"additional","affiliation":[{"name":"Medical Research Institute of New Zealand, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Beasley","sequence":"additional","affiliation":[{"name":"Medical Research Institute of New Zealand, Wellington, New Zealand"},{"name":"Victoria University Wellington, Wellington, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,8,3]]},"reference":[{"key":"2025121602200494000_7.8.e017766.1","doi-asserted-by":"crossref","unstructured":"Wald A , Corey L . ersistence in the population: epidemiology, transmission. In: Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press, 2007.","DOI":"10.1017\/CBO9780511545313.037"},{"key":"2025121602200494000_7.8.e017766.2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.11.1137"},{"key":"2025121602200494000_7.8.e017766.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-0825.2006.01202.x"},{"key":"2025121602200494000_7.8.e017766.4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.7.2238-2243.2002"},{"key":"2025121602200494000_7.8.e017766.5","doi-asserted-by":"publisher","DOI":"10.1002\/iub.578"},{"key":"2025121602200494000_7.8.e017766.6","first-page":"289","article-title":"Honey has an antifungal effect against candida species","volume":"2006","author":"Irish","year":"2005","journal-title":"Med Mycol"},{"key":"2025121602200494000_7.8.e017766.7","first-page":"47","article-title":"Antiviral activities of Honey, Royal Jelly, and Acyclovir against HSV-1","volume":"26","author":"Hashemipour","year":"2014","journal-title":"Wounds"},{"key":"2025121602200494000_7.8.e017766.8","doi-asserted-by":"publisher","DOI":"10.1177\/1534734605286014"},{"key":"2025121602200494000_7.8.e017766.9","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/jocd.12058","article-title":"Honey in dermatology and skin care: a review","volume":"12","author":"Burlando","year":"2013","journal-title":"J Cosmet Dermatol"},{"key":"2025121602200494000_7.8.e017766.10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/wrr.12117","article-title":"Honey: an immunomodulator in wound healing","volume":"22","author":"Majtan","year":"2014","journal-title":"Wound Repair Regen"},{"key":"2025121602200494000_7.8.e017766.11","doi-asserted-by":"publisher","DOI":"10.1177\/014107689909200604"},{"key":"2025121602200494000_7.8.e017766.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007651","article-title":"Randomised controlled trial of topical kanuka honey for the treatment of rosacea","volume":"5","author":"Braithwaite","year":"2015","journal-title":"BMJ Open"},{"key":"2025121602200494000_7.8.e017766.13","doi-asserted-by":"crossref","unstructured":"Miguel MG , Antunes MD , Faleiro ML . Honey as a complementary medicine. Integr Med Insights 2017;12.doi:10.1177\/1178633717702869","DOI":"10.1177\/1178633717702869"},{"key":"2025121602200494000_7.8.e017766.14","doi-asserted-by":"crossref","unstructured":"Saikaly SK , Khachemoune A . Honey and Wound Healing : an Update. 2017:237\u201351.","DOI":"10.1007\/s40257-016-0247-8"},{"key":"2025121602200494000_7.8.e017766.15","first-page":"22","article-title":"Up-to-date use of honey for Burns treatment","volume":"27","author":"Zbuchea","year":"2014","journal-title":"Ann Burns Fire Disasters"},{"key":"2025121602200494000_7.8.e017766.16","first-page":"MT94","article-title":"Topical honey application vs. acyclovir for the treatment of recurrent herpes simplex lesions","volume":"10","author":"Al-Waili","year":"2004","journal-title":"Med Sci Monit"},{"key":"2025121602200494000_7.8.e017766.17","first-page":"849","article-title":"The In\u00a0Vitro Anti2Viral Activity of Honey on Type 1 Herpes Simplex Virus Assistant\u00a0Professor , Department of Oral Medicine , School of Dentistry\u00a0, Shiraz\u00a0University of Medical","volume":"5","author":"Ghapanchi","year":"2011","journal-title":"Aust J Basic Appl Sci"},{"key":"2025121602200494000_7.8.e017766.18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.aimed.2014.09.001","article-title":"Randomised controlled trial of topical kanuka honey for the treatment of cold sores","volume":"1","author":"Fingleton","year":"2014","journal-title":"Adv Integr Med"},{"key":"2025121602200494000_7.8.e017766.19","doi-asserted-by":"crossref","unstructured":"Skulason S , Holbrook WP , Thormar H , et al . A study of the clinical activity of a gel combining monocaprin and doxycycline : a novel treatment for herpes labialis. 2012:61\u20137.","DOI":"10.1111\/j.1600-0714.2011.01037.x"},{"key":"2025121602200494000_7.8.e017766.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1079-2104(99)70164-2"},{"key":"2025121602200494000_7.8.e017766.21","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.1987.0211"},{"key":"2025121602200494000_7.8.e017766.22","unstructured":"Hro A , Mann H , Dickersin K , et al . Research and Reporting methods annals of internal medicine SPIRIT 2013 Statement : defining Standard Protocol items for clinical trials. 1, 2015."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-017766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:20:15Z","timestamp":1765880415000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-017766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,3]]},"published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1136\/bmjopen-2017-017766"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-017766","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}